Similar to BCR-ABL1-positive ALL, patients with BCR-ABL-like ALL have a reduced five-year disease-free survival (DFS), and they are caused by the different mutations previously described, which similarly result in the overexpression and altered modulation of common surface receptor/kinase signaling pathways. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.